Sinovac Biotech Ltd. Files December 2025 6-K Report
Ticker: SVA · Form: 6-K · Filed: Dec 17, 2025
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, corporate-filing
TL;DR
Sinovac Biotech filed its December 2025 6-K, confirming its Beijing HQ and 20-F filing status.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K on January 30, 2026, reporting for the month of December 2025. The filing indicates the company's principal executive offices are located at No. 39 Shangdi Xi Road, Haidian District, Beijing, People's Republic of China. The company is registered under SEC file number 001-32371 and is required to file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates on Sinovac Biotech's corporate information and reporting status, which is important for investors tracking the company's compliance and operational details.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing basic corporate information and not announcing significant financial or operational changes.
Key Numbers
- December 2025 — Reporting Period (The period covered by this Form 6-K)
- 20251217 — Conformed Period of Report (The date as of which the report is conformed)
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Filer of the report
- 001-32371 (company) — SEC File Number
- Andrew Y. Yan (person) — Signatory for the company
- Beijing (location) — Location of principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of December 2025, providing routine corporate information.
Where are Sinovac Biotech Ltd.'s principal executive offices located?
The principal executive offices are located at No. 39 Shangdi Xi Road, Haidian District, Beijing, 100085, People's Republic of China.
What is the SEC file number for Sinovac Biotech Ltd.?
The SEC file number for Sinovac Biotech Ltd. is 001-32371.
Does Sinovac Biotech Ltd. file annual reports under Form 20-F or Form 40-F?
Sinovac Biotech Ltd. files annual reports under cover of Form 20-F.
Who signed this Form 6-K on behalf of Sinovac Biotech Ltd.?
The report was signed by Andrew Y. Yan, pursuant to the requirements of the Securities Exchange Act of 1934.
Filing Stats: 149 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2026-01-30 15:23:47
Filing Documents
- ea0270047-6k_sinovac.htm (6-K) — 9KB
- ea027004701ex99-1_sinovac.htm (EX-99.1) — 10KB
- 0001213900-25-122528.txt ( ) — 20KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Chairman of the Board Date: December 17, 2025 1 Exhibit Index Exhibit 99.1 Press Release 2